Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

Heart

Volumn 103, Issue 8, 2017, Pages 623-628

  Bahit, M Cecilia ^a   Lopes, Renato D ^b   Wojdyla, Daniel M ^b   Held, Claes ^c   Hanna, Michael ^d   Vinereanu, Dragos ^e   Hylek, Elaine M ^f   Verheugt, Freek ^g   Goto, Shinya ^h   Alexander, John H ^b   Wallentin, Lars ^c   Granger, Christopher B ^b  

^a Grupo Oroño   (Argentina)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d BRISTOL MYERS SQUIBB   (United States)

^e CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^g ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; PLACEBO; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; ECCHYMOSIS; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART SURGERY; HEMATOMA; HEMATURIA; HUMAN; INCIDENCE; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; ASIA; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DRUG SUBSTITUTION; EUROPE; HEMORRHAGE; MIDDLE AGED; MORTALITY; NORTH AMERICA; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTOR; SOUTH AND CENTRAL AMERICA; STROKE; THROMBOEMBOLISM; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ASIA; ATRIAL FIBRILLATION; DRUG SUBSTITUTION; EUROPE; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; LATIN AMERICA; MALE; MIDDLE AGED; NORTH AMERICA; PATIENT SAFETY; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84994784170     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-309901     Document Type: Article

References (15)

1. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:590-2.
2. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
6. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141-7.
7. Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J 2015;36:1264-72.
8. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-9.
9. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
10. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72.
11. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
12. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2014;63:891-900.
13. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
14. Strate LL. Lower GI bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am 2005;34:643-64.
15. Weitz JI. New oral anticoagulants: a view from the laboratory. Am J Hematol 2012;87:S133-6.